Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

Journal of Clinical Oncology

Volumn 22, Issue 5, 2004, Pages 935-942

  Peng, Bin ^a   Hayes, Michael ^a   Resta, Debra ^a   Racine Poon, Amy ^a   Druker, Brian J ^a   Talpaz, Moshe ^a   Sawyers, Charles L ^a   Rosamilia, Marianne ^a   Ford, John ^a   Lloyd, Peter ^a   Capdeville, Renaud ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; CELL PROLIFERATION; CHROMOSOME; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; HEMATOLOGY; HUMAN; LEUKOCYTE; MYELOID LEUKEMIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STEADY STATE; ADULT; AGED; BIOAVAILABILITY; CHRONIC MYELOID LEUKEMIA; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HOSPITALIZATION; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; SURVIVAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 1542608328     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.03.050     Document Type: Article

References (21)

1. Faderl S, Talpaz M, Estrov Z, et al: The biology of chronic myeloid leukemia. N Engl J Med 341:164-172, 1999
2. Sawyers CL: Chronic myeloid leukemia. N Engl J Med 340:1330-1340, 1999
3. Buchdunger E, Zimmerman J, Mett H, et al: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100-104, 1996
4. Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566, 1996
5. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
6. Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001
7. Bakhtiar R, Lohne J, Ramos L, et al: High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 768: 325-340, 2002
8. Fuseau E, Sheiner LB: Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model. Clin Pharmacol Ther 35:733-741, 1984
9. Deininger MW, Goldman JM, Lydon N, et al: The tyrosine kinase inhibitor CGP57148B se lectively inhibits the growth of BCR-ABL-positive cells. Blood 90:3691-3698, 1997
10. Gambacorti-Passerini C, le Coutre P, Mologni L, et al: Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 23:380-394, 1997
11. Wilkinson GR: Cytochrome P4503A (CYP3A) metabolism: Prediction of in vivo activity in humans. J Pharmacokinet Biopharm 24: 475-490, 1996
12. Baker SD, Verweij J, Rowinsky EK, et al: Role of body surface area in dosing of investigational anticancer agents in adults 1991-2001. J Natl Cancer Inst 94:1883-1888, 2002
13. Bolton AE, Peng B, Hubert M, et al: Effect of rifampin (a potent inducer of CYP450 3A4) on the pharmacokinetics of Gleevec (Glivec, STI571, imatinib). Blood 100:214b, 2002 (abstr 4364)
14. Calvert AH: Dose optimisation of carboplatin in adults. Anticancer Res 14:2273-2278, 1994
15. Jakobsen P, Bastholt L, Dalmark M, et al: A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement. Cancer Chemother Pharmacol 28:465-469, 1991
16. Kearns CM, Gianni L, Egorin MJ: Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 22:16-23, 1995 (suppl 6)
17. Joel SP, Shah R, Slevin ML: Etoposide dosage and pharmacodynamics. Cancer Chemother Pharmacol 34:S69-S75, 1994 (suppl)
18. Sawyers CL, Hochhaus A, Feldman E, et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 99:3530-3539, 2002
19. Shah NP, Nicoll JM, Nagar B, et al: Multiple Bcr-abl kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125, 2002
20. Hochhaus A, Kreil S, Corbin AS, et al: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190-2196, 2002
21. Gambacorti-Passerini C, Barni R, le Coutre P, et al: Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL (+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 92:1641-1650, 2000